Anrotinib has certain efficacy for patients with esophageal cancer, and it is recommended to go to hospital for standardized treatment.
Anrotinib belongs to anti-angiogenic inhibitors, which can inhibit tumor cell proliferation and infiltration by inhibiting tumor neovascularization, and is commonly used in advanced or metastatic non-small cell lung cancer, and is recommended by the current guidelines to be used in more than the second-line treatment for recurrent and metastatic esophageal cancer, and the clinical trials have proved that anrotinib can significantly improve the progression-free survival time of advanced esophageal cancer.
Anrotinib can cause hypertension, hand and foot skin reactions, abnormal liver function, abnormal thyroid function, proteinuria, diarrhea, hyperlipidemia, and bleeding. It is contraindicated for those who are allergic to Anrotinib, those with risk of hemoptysis and severe renal insufficiency, pregnant and lactating women.
It is recommended to use the drug under the guidance of a doctor.